Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD19/CD22 4th Generation CAR-T Cells (4SCAR19/22) Followed by Interleukin-2 Treating Pediatric Relapsed and Refractory B Cell Malignancies

NCT03098355 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT03098355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03098355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD19/CD22 4th Generation CAR-T Cells (4SCAR19/22) Followed by Interleukin-2 Treating Pediatric Relapsed and Refractory B Cell Malignancies
Lead sponsor
Zhujiang Hospital
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 30, 2017
Completion date
December 31, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia, b-cell lymphoma